Novel Small Molecules against Two Binding Sites of Wnt2 Protein as potential Drug Candidates for Colorectal Cancer: A Structure Based Virtual Screening Approach

Document Type : Research article

Authors

1 Department and Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran.

2 Department of Molecular Medicine, Pasteur Institute of Iran, Tehran, Iran.

Abstract

Wnts are the major ligands responsible for activating Wnt signaling pathway through binding to Frizzled proteins (Fzd) as the receptors. Among these ligands, Wnt2 plays the main role in the tumorigenesis of several human cancers especially colorectal cancer (CRC). Therefore, it can be considered as a potential drug target.The aim of this study was to identify potential drug candidates against two binding sites of Wnt2. Structure-based virtual screening approaches were applied to identify compounds against binding sites of Wnt2 for inhibiting the interaction Wnt2 and Fzd receptors. The best hit compounds from molecular docking of National Cancer Institute diversity set II database were used for structural similarity search on ZINC database, obtaining large hit compounds query to perform a virtual screening and retrieving potential lead compounds. Eight lead compounds were selected while their binding affinity, binding modes interactions, and molecular dynamics simulations studies were assessed. Molecular docking studies showed that eight selected lead compounds can bind to the desired binding sites of Wnt2 in a high affinity manner. Bioavailability analysis of the selected lead compounds indicated that they possessed significant drug like properties. Thus, these lead compounds were considered as potential drug candidates for inhibiting Wnt signaling pathway through combining with the binding sites of Wnt2 and hindering the interaction of Wnt2 and Fzd receptors. Our findings suggest that Wnt2 binding sites may be a useful target for treatment for CRC fueling the future efforts for developing new compounds against Wnt signaling pathway.

Graphical Abstract

Novel Small Molecules against Two Binding Sites of Wnt2 Protein as potential Drug Candidates for Colorectal Cancer: A Structure Based Virtual Screening Approach

Keywords


(1) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int . J.  Cancer. (2010) 127:  2893-917.
(2) Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A,Jemal A. Colorectal cancer statistics, 2017. CA. Cancer.  J. Clin. (2017) 67:177-93.
(3) Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim . Biophys. Acta. -Reviews on Cancer. (2006) 1766 :184-96.
(4)  Polakis P. Wnt signaling in cancer. Cold. Spring Harb Perspect . Biol. (2012) 4: a008052.
(5)  Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. (2012) 149:1192-205.
(6)  Janssens N, Janicot M, Perera T. The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest. New. Drugs. (2006) 24:263.
(7)  Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY, Reguart  N,  Batra  S,  Mikami T, David M. Jablons D. Wnt2 as a new therapeutic target in malignant pleural mesothelioma.  Int. J. Cancer. (2005) 117:326-32.
(8)  Huang C, Ma R, Xu Y, Li N, Li Z, Yue J, Haixin L, Yan GDaliang Q. Wnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway.  Am. J. Cancer. Res. (2015) 5:1032.
(9)  Jung Y-S, Jun S, Lee SH, Sharma A, Park J-I. Wnt2 complements Wnt/β-catenin signaling in colorectal cancer. Oncotarget. (2015) 6:37257.
(10)  Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong KL, Kwong DL, Guan XY. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/β-catenin signalling pathway. Gut. (2011) 60: 1635-43.
(11)  Ricken A, Lochhead P, Kontogiannea M, Farookhi R. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology. (2002) 143: 2741-9.
(12)  Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM, You L. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC. cancer. (2013)13:316.
(13) Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. (2012) 487: 510.
(14)  Katoh M. WNT2 and human gastrointestinal cancer. Int . J. Mol. Med. (2003) 12: 811-6.
(15) Shi Y, He B, Kuchenbecker KM, You L, Xu Z, Mikami I, Yagui‐Beltran A, Clement G, Lin YC, Okamoto J, Bravo DT.. Inhibition of Wnt‐2 and galectin‐3 synergistically destabilizes β‐catenin and induces apoptosis in human colorectal cancer cells. Int. J. cancer. (2007) 121: 1175-81.
(16) Janda CY, Waghray D, Levin AM, Thomas C, Garcia KC. Structural basis of Wnt recognition by Frizzled. Science. (2012)  337 :59-64.
(17) Kalhor H, Poorebrahim M, Rahimi H, Shabani AA, Karimipoor M, Eidgahi MR, Teimoori-Toolabi L. Structural and dynamic characterization of human Wnt2-Fzd7 complex using computational approaches. J.  Mol. Model. (2018) 24 :274.
(18) Agostino M, Pohl SÖ-G, Dharmarajan A. Structure-based prediction of Wnt binding affinities for Frizzled-type cysteine-rich domains. J. Biol. Chem. (2017) 292: 11218-29.
(19)  Kapetanovic I. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem. Biol. Interact.. (2008) 171: 165-76.
(20) Pugazhendhi D, Umamaheswari T. Insilico Methods in Drug Discovery-A Review. Int. J. (2013) 3.
(21) Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol. R ev. (2014) 66: 334-95.
(22) Shiri F, Pirhadi S, Rahmani A. Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening. J.  Recept . Signal. Transduct. Res. (2018) 38: 37-47.
(23) Shiri F, Pirhadi S, Ghasemi JB. Dynamic structure based pharmacophore modeling of the Acetylcholinesterase reveals several potential inhibitors. J. Biomol. Struct. Dyn. (2018) 37:1800-12.
(24) Hearnshaw SJ, Edwards MJ, Stevenson CE, Lawson DM, Maxwell A. A new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. J. Mol. Biol.(2014) 426: 2023-33.
(25) Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput Chem. (2009) 30: 2785-91.
(26)Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J. Chem. Inf. Model. (2013)  53: 1893-904.
(27) Dahlin JL, Nissink JW, Strasser JM, Francis S, Higgins L, Zhou H, Zhang Z, Walters M. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J. Med. Chem. (2015) 58: 2091-113.
(28) Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model. (2015) 55: 460-73.
(29) Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E.. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. (2015) 1: 19-25.
(30) SchuÈttelkopf AW, Van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. Acta. Crystallogr D. Struct. Biol. (2004) 60:1355-63.
(31) DeLano WL. Pymol: An open-source molecular graphics tool. CCP4. Newsletter. Pro. Crystallogr. (2002) 40: 82-92.
(32) Laskowski RA, Swindells MB. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J. Chem. Inf. Model. ( 2011) 2778-2786.
(33) Systèmes D. BIOVIA, Discovery Studio Modeling Environment. Dassault Systèmes Biovia: San Diego, CA, USA. 2016.
(34) Kumar S, Žigman M, Patel TR, Trageser B, Gross JC, Rahm K, Boutros M, Gradl D, Steinbeisser H, Holstein T, Stetefeld J. Molecular dissection of Wnt3a-Frizzled8 interaction reveals essential and modulatory determinants of Wnt signaling activity. BMC biol. (2014) 12: 44.
(35) Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. (1997) 23: 3-25.
(36) Van De Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise?.  Nat. Rev. Drug discov. (2003) 2: 192.
(37)  Lombardo F, Gifford E, Shalaeva MY. In silico ADME prediction: data, models, facts and myths. Mini. Rev. Med. Chem. (2003) 3: 861-75.
(38) Pirhadi S, Ghasemi JB. Pharmacophore identification, molecular docking, virtual screening, and in silico ADME studies of non‐nucleoside reverse transcriptase inhibitors. Mol. Inform.  (2012)31: 856-66.
(39) Reichel A, Begley DJ. Potential of immobilized artificial membranes for predicting drug penetration across the blood− brain barrier. Pharm. Res. (1998) 15: 1270-4.
(40) Sadeghi S, Poorebrahim M, Rahimi H, Karimipoor M, Azadmanesh K, Khorramizadeh MR, Teimoori-Toolabi L. In Silico studying of the whole protein structure and dynamics of Dickkopf family members showed that N terminal domain of Dickkopf 2 in contrary to other Dickkopfs facilitates its interaction with Low Density Lipoprotein Receptor Related Protein 5/6. J. Biomol. Struct. Dyn. (2018) 37: 2564-2580.
(41) Song L, Li Y, He B, Gong Y. Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer. Clin. Colorectal. Cancer. (2015) 14:133-45.
(42) Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG. Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. (2009) 5: 100.
(43) Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK. An Antagonist of Dishevelled Protein-Protein Interaction Suppresses β-Catenin–Dependent Tumor Cell Growth. Cancer. Res. (2007) 67: 573-9.
(44) Grandy D, Shan J, Zhang X, Rao S, Akunuru S, Li H, Zhang Y, Alpatov I, Zhang XA, Lang RA, Shi DL. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem. (2009) 284: 16256-63.
(45) Shan J, Shi D-L, Wang J, Zheng J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry. (2005) 44: 15495-503.
(46) Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. U S A. (2012) 109: 11717-22.
(47) Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer. Res. ( 2012) 72: 2822-32.
(48) Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, Gradl D, Paulsen JE, Machonova O, Dembinski JL, Dinh H. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer. Res. (2011) 71: 197-205.
(49) Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer. cell. (2004) 5: 91-102.
(50) Janda CY, Dang LT, You C, Chang J, de Lau W, Zhong ZA, Yan KS, Marecic O, Siepe D, Li X, Moody JD. Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling. Nature. (2017) 545: 234.
(51) Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors and multiple transcription factors. J. Bio. Chem. (2006) 281: 22429-33.
(52) Pećina-Šlaus N. Wnt signal transduction pathway and apoptosis: a review. Cancer. Cell Int. (2010) 10: 22.
(53) Hammad MA, Azam SS. Structural dynamics and inhibitor searching for Wnt-4 protein using comparative computational studies. Drug. Des. Devel. Ther. (2015) 9: 2449.
(54) Katoh M. Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int. J. Oncol. (2001) 19 : 1003-7.
(55) Holcombe R, Marsh J, Waterman M, Lin F, Milovanovic T, Truong T. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol.Pathol. (2002) 55: 220.
(56) Smith K, Bui T, Poulsom R, Kaklamanis L, Williams G, Harris A. Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br. J. Cancer. (1999) 81: 496-502.
(57) Mohamed R, Degac J, Helms V. Composition of overlapping protein-protein and protein-ligand interfaces. PLoS One. (2015) 10: e0140965.
(58) Chen K, Kurgan L. Investigation of atomic level patterns in protein—small ligand interactions. PLoS One. (2009) 4: e4473.
(59)de Freitas RF, Schapira M. A systematic analysis of atomic protein–ligand interactions in the PDB. Med. Chem. Comm. (2017) 8: 1970-81.
(60) Leung CS, Leung SS, Tirado-Rives J, Jorgensen WL. Methyl effects on protein–ligand binding. J. Med. Chem. (2012) 55: 4489-500.
(61) Barreiro EJ, Kümmerle AE, Fraga CA. The methylation effect in medicinal chemistry. Chem. Rev. (2011) 111: 5215-46.
(62) Kumar K, Woo SM, Siu T, Cortopassi WA, Duarte F, Paton RS. Cation–π interactions in protein–ligand binding: theory and data-mining reveal different roles for lysine and arginine. Chem. Sci. (2018) 9: 2655-65.
(63) Simard JR, Getlik M, Grütter C, Pawar V, Wulfert S, Rabiller M, Rauh D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J. Am. Chem. Soc. (2009) 131: 13286-96.
(64) Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ. . Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure. (2008) 16: 460-7.
(65) Alapour S, Zamisa SJ, Silva JR, Alves CN, Omondi B, Ramjugernath D, Koorbanally NA. Investigations into the flexibility of the 3D structure and rigid backbone of quinoline by fluorine addition to enhance its blue emission. Cryst. Eng. Comm. (2018) 20: 2316-23.
(66) Shah P, Westwell AD. The role of fluorine in medicinal chemistry. J. Enzyme. Inhib. Med. Chem. (2007) 22: 527-40.
(67) Isanbor C, O'Hagan D. Fluorine in medicinal chemistry: a review of anti-cancer agents. J. Fluorine. Chem. (2006) 127: 303–319.
(68) Yokoyama M, Naganawa S, Yoshimura K, Matsushita S, Sato H. Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop. PLoS One. (2012) 7: e37530.
(69) Pushie MJ, George GN. Active-site dynamics and large-scale domain motions of sulfite oxidase: A molecular dynamics study. J. Phys. Chem B. (2010) 114: 3266-75.
(70)Azam SS, Mirza AH. Role of thumb index fold in Wnt-4 protein and its dynamics through a molecular dynamics simulation study. J. Mol. Liq. (2014) 198: 313-21.
(71) Gane PJ, Chan AE. Molecular Fields in Ligand Discovery. Methods. Mol. Biol. (2013) 1008: 479-99.